Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Noxopharm Ltd V.NOX


Primary Symbol: NOXOF

Noxopharm Limited is a biotech company. It is engaged in discovering and developing novel treatments for cancer and inflammation, including a pioneering technology to enhance messenger ribonucleic acid (mRNA) vaccines. It utilizes specialist in-house capabilities and partnerships with researchers to build a pipeline of new proprietary drugs based on two technology platforms: Chroma (oncology) and Sofra (inflammation, autoimmunity, and mRNA vaccine enhancement). Chroma is a technology platform focused on the development of multiple drug candidates, primarily for cancer treatment. The Sofra technology platform has a pipeline of proprietary drugs based on oligonucleotides, the building blocks of deoxyribonucleic acid (DNA), with a focus on mRNA vaccines and the treatment of autoimmune and inflammatory diseases. SOF-VAC has applications in the treatment of excessive inflammatory responses associated with specialized inflammatory receptors in the body known as Toll-like receptor 7.


OTCPK:NOXOF - Post by User

Bullboard Posts
Post by taco06on Dec 08, 2010 7:19pm
385 Views
Post# 17821088

Aurizon's Bright Horizon

Aurizon's Bright Horizon

BRIAN CHRISTIE, National Bank Financial (12/07/2010)
"Aurizon reported results from two additional holes on the Marban Block property, which is located in the Malartic gold camp in the Abitibi region of Quebec. These holes are part of a planned C$5.9m program of 50,000 metres of drilling designed to better define and increase the near-surface gold resources at the Marban and Norlartic deposits. Aurizon can earn up to a 65% interest in the project from NioGold Mining (NOX, TSX-V, not rated) by incurring C$20m in expenditures over three years, completing an updated NI 43-101–compliant resource estimate and making a payment on 50% of the total resources defined in the updated estimate. . .To date, 36 holes and two extensions have been completed, and two holes are in progress for a total of 11,313 metres. Assays for 22 holes are currently pending. We view this morning’s news as positive, as these drill results from Marban continue to confirm the potential for both bulk tonnage mineralization and higher grade ore shoots at shallow depths."

Bullboard Posts

USER FEEDBACK SURVEY ×

Be the voice that helps shape the content on site!

At Stockhouse, we’re committed to delivering content that matters to you. Your insights are key in shaping our strategy. Take a few minutes to share your feedback and help influence what you see on our site!

The Market Online in partnership with Stockhouse